Exxel Pharma is a development stage company that combines world-class leadership, know-how and industry experience to develop medicines for significant unmet medical needs.
Exxel Pharma is focused on development of small-molecule therapeutics for safe, non-addictive treatment of a pain, PTSD and substance (e.g. opioid) use disorders.
Exxel Pharma’s pipeline counts two functionally distinct FAAH inhibitors, URB597 and URB937. URB597 is globally active, whereas URB937 is peripherally restricted. Both molecules were developed at UC Irvine and enhance endocannabinoid signaling.
The endocannabinoid system is composed of endocannabinoids and cannabinoid receptors, and is involved in the regulation of key physiological and pathological processes. Endocannabinoids are natural, lipid-based signaling molecules.
Exxel Pharma is a private, development stage company managed by a team of experienced biotech executives and entrepreneurs. The Company is focused on development of small-molecule therapeutics for safe, non-addictive treatment of a pain, PTSD and substance (e.g. opioid) use disorders.
Exxel’s two lead therapeutics, URB937 and URB597, were developed at the University of California, Irvine (UCI), and are covered by multiple issued and pending patents.Contact Us